Autoimmune Diseases  >>  ligelizumab (QGE031)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ligelizumab (QGE031) / Novartis
NCT01688882 / 2012-003370-10: Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment

Terminated
2
20
Japan, US, Europe, RoW
QGE031, Placebo
Novartis Pharmaceuticals
Bullous Pemphigoid
03/15
03/15

Download Options